Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivo

Helmrich, A., Lee, S., O'Brien, P., Dorken, B., Lowe, S. W., Schrock, E., Schmitt, C. A. (June 2005) Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivo. Oncogene, 24 (26). pp. 4174-4182. ISSN 0950-9232

URL: https://www.ncbi.nlm.nih.gov/pubmed/15824738
DOI: 10.1038/sj.onc.1208600

Abstract

Predicting responsiveness to anticancer therapy based on molecular findings at diagnosis is important to optimize treatment decisions. Although clinical outcome correlates with distinct mutations in some cancer entities, treatment responses within these lesion-stratified subgroups still remain heterogeneous, underscoring the need for additional prognosticators. We previously demonstrated that defined genetic defects at the INK4a/ARF locus, which encodes the tumor suppressors p16(INK4a) and ARF, not only accelerated lymphomagenesis in the E mu-myc transgenic mouse but also interfered with treatment sensitivity. In this study, we take a nonbiased genome-wide approach to examine whether the responsiveness of these lymphomas can be further stratified based on cytogenetic information at diagnosis. Indeed, using spectral karyotyping, comparative genomic hybridization, and fluorescence in situ hybridization in 38 primary lymphomas, we find recurrent cytogenetic alterations that re. ne the predictive value of INK4a/ARF lesions on drug responses in vivo: gain of chromosome 14, which was never detected in INK4a/ ARFnull lymphomas, defined an ARFnull subgroup with superior treatment outcome. Gain of chromosome 6 was identified as a recurrent chromosomal aberration that predisposed ARFnull tumors to their subsequent INK4a loss during therapy. These data illustrate how cytogenetic information from cancer specimens might complement established prognostic markers and may improve anticancer treatment strategies.

Item Type: Paper
Uncontrolled Keywords: cytogenetic analysis chemoresistance INK4a/ARF lymphoma mouse model ACUTE LYMPHOBLASTIC-LEUKEMIA acute lymphoblastic leukemia CHRONIC LYMPHOCYTIC-LEUKEMIA chronic lymphocytic leukemia GENOMIC ABERRATIONS genomic aberrations CANCER-THERAPY cancer therapy C-MYC P16(INK4A) INK4A apoptosis SENESCENCE senescence RELAPSE relapse mice mouse
Subjects: diseases & disorders > cancer
diseases & disorders > cancer > drugs and therapies
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > DNA, RNA structure, function, modification > suppressor
CSHL Authors:
Communities: CSHL labs > Lowe lab
Depositing User: CSHL Librarian
Date: June 2005
Date Deposited: 13 Jan 2012 15:57
Last Modified: 03 May 2018 20:20
Related URLs:
URI: http://repository.cshl.edu/id/eprint/22590

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving